French Innovative Leukemia Organisation
Clinical trials sponsored by French Innovative Leukemia Organisation, explained in plain language.
-
New combo aims to stop leukemia from coming back
Disease control Not yet recruitingThis study tests whether adding ivosidenib to oral azacitidine (Onureg) can help prevent acute myeloid leukemia (AML) from returning in patients over 55 who have a specific IDH1 mutation and are already in remission after chemotherapy. About 60 participants will take both pills d…
Phase: PHASE2 • Sponsor: French Innovative Leukemia Organisation • Aim: Disease control
Last updated May 17, 2026 07:07 UTC
-
New hope for rare blood cancer: drug combo aims for remission
Disease control Not yet recruitingThis study tests a combination of two drugs, tagraxofusp and venetoclax, in adults with a rare and aggressive blood cancer called BPDCN who have not yet been treated. The main goal is to see if this combo can make the cancer disappear or shrink significantly after three months. P…
Phase: PHASE2 • Sponsor: French Innovative Leukemia Organisation • Aim: Disease control
Last updated May 17, 2026 06:49 UTC
-
New pill combo shows promise for rare blood cancer
Disease control Not yet recruitingThis study tests a combination of two oral medications, zanubrutinib and BGB-11417, in people with Waldenström macroglobulinemia who have already received at least one prior treatment. The goal is to see if the combo can shrink or control the cancer better than current options. A…
Phase: PHASE2 • Sponsor: French Innovative Leukemia Organisation • Aim: Disease control
Last updated May 15, 2026 11:54 UTC